Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Study sponsor: Emergent BioSolutions
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-06-17Actual
Enrollment · participants65Actual
Source updated2024-03-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.